18 July, 2023
Hot Off The Press
iPSC (induced pluripotent stem cells) can be engineered to produce a protein called glial cell line-derived neurotrophic factor (GDNF), which helps sustain diseased neurons whether they are causing Retinitis Pigmentosa or other neurodegenerative diseases. If we can keep the diseased neurons healthier for longer, then we can slow disease progression. Researchers are even looking at reprogramming the patient’s own red blood cells to make GDNF.
A new study shows that total RPE65 protein levels in mice with autosomal dominant retinitis pigmentosa were doubled following subretinal delivery of adeno-associated virus (AAV)-RPE65 gene supplementation.
The illustrations in this new trial French book are tactile with sounds associated. This is particularly useful for children who have never had any vision for whom the usual illustrations are difficult to interpret.
It has now become possible to attach drugs to common proteins in the eye for slow release instead of using an implantable device or injections. Artificial Intelligence has been used to find the most useful peptide (string of amino acids) which can attach the therapeutic drug to an intraocular protein. This study attached the drug brimonidine to melanin which is commonly found in the eye, with some success.
This has potential use for glaucoma and macular degeneration.
Making use of the large databank in Moorfields Eye Hospital in the UK, and the use of AI has managed to predict IRD diagnoses with over 70% accuracy already in a study. The researchers are talking about potentially using the data in routine screening CT scans to help early diagnosis in the future. This method uses the physical characteristics or (phenotype) rather than the genotype for diagnosis.